|
1
|
Ding ZC, Blazar BR, Mellor AL, Munn DH and
Zhou G: Chemotherapy rescues tumor-driven aberrant CD4+
T-cell differentiation and restores an activated polyfunctional
helper phenotype. Blood. 115:2397–2406. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhao J, Cao Y, Lei Z, Yang Z, Zhang B and
Huang B: Selective depletion of
CD4+CD25+Foxp3+ regulatory T cells
by low-dose cyclophosphamide is explained by reduced intracellular
ATP levels. Cancer Res. 70:4850–4858. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sistigu A, Viaud S, Chaput N, Bracci L,
Proietti E and Zitvogel L: Immunomodulatory effects of
cyclophosphamide and implementations for vaccine design. Semin
Immunopathol. 33:369–383. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Matar P, Rozados VR, Gervasoni SI and
Scharovsky GO: Th2/ Th1 switch induced by a single low dose of
cyclophosphamide in a rat metastatic lymphoma model. Cancer Immunol
Immunother. 50:588–596. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liu JY, Wu Y, Zhang XS, Yang JL, Li HL,
Mao YQ, Wang Y, Cheng X, Li YQ, Xia JC, et al: Single
administration of low dose cyclophosphamide augments the antitumor
effect of dendritic cell vaccine. Cancer Immunol Immunother.
56:1597–1604. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Veltman JD, Lambers MEH, van Nimwegen M,
de Jong S, Hendriks RW, Hoogsteden HC, Aerts JG and Hegmans JP:
Low-dose cyclophosphamide synergizes with dendritic cell-based
immunotherapy in antitumor activity. J Biomed Biotechnol.
2010:7984672010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Balkow S, Loser K, Krummen M, Higuchi T,
Rothoeft T, Apelt J, Tuettenberg A, Weishaupt C, Beissert S and
Grabbe S: Dendritic cell activation by combined exposure to
anti-CD40 plus interleukin (IL)-12 and IL-18 efficiently stimulates
anti-tumor immunity. Exp Dermatol. 18:78–87. 2009. View Article : Google Scholar
|
|
8
|
Brunner C, Seiderer J, Schlamp A,
Bidlingmaier M, Eigler A, Haimerl W, Lehr HA, Krieg AM, Hartmann G
and Endres S: Enhanced dendritic cell maturation by TNF-alpha or
cytidine-phosphate-guanosine DNA drives T cell activation in vitro
and therapeutic anti-tumor immune responses in vivo. J Immunol.
165:6278–6286. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rossowska J, Pajtasz-Piasecka E, Szyda A,
Krawczenko A, Zietara N and Dus D: Tumour antigen-loaded mouse
dendritic cells maturing in the presence of inflammatory cytokines
are potent activators of immune response in vitro but not in vivo.
Oncol Rep. 21:1539–1549. 2009.PubMed/NCBI
|
|
10
|
Pajtasz-Piasecka E and Indrová M:
Dendritic cell-based vaccines for the therapy of experimental
tumors. Immunotherapy. 2:257–268. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rossowska J, Pajtasz-Piasecka E, Ryśnik O,
Wojas J, Krawczenko A, Szyda A and Duś D: Generation of antitumor
response by IL-2-transduced JAWS II dendritic cells. Immunobiology.
216:1074–1084. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rossowska J, Pajtasz-Piasecka E, Anger N,
Wojas-Turek J, Kicielińska J, Piasecki E and Duś D:
Cyclophosphamide and IL-12-transduced DCs enhance the antitumor
activity of tumor antigen-stimulated DCs and reduce Tregs and MDSCs
number. J Immunother. 37:427–439. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Steinman RM: Decisions about dendritic
cells: Past, present, and future. Annu Rev Immunol. 30:1–22. 2012.
View Article : Google Scholar
|
|
14
|
Coquerelle C and Moser M: DC subsets in
positive and negative regulation of immunity. Immunol Rev.
234:317–334. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kalinski P, Urban J, Narang R, Berk E,
Wieckowski E and Muthuswamy R: Dendritic cell-based therapeutic
cancer vaccines: What we have and what we need. Future Oncol.
5:379–390. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Palucka K, Ueno H, Roberts L, Fay J and
Banchereau J: Dendritic cell subsets as vectors and targets for
improved cancer therapy. Curr Top Microbiol Immunol. 344:173–192.
2011.
|
|
17
|
Fong L, Brockstedt D, Benike C, Breen JK,
Strang G, Ruegg CL and Engleman EG: Dendritic cell-based
xenoantigen vaccination for prostate cancer immunotherapy. J
Immunol. 167:7150–7156. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nencioni A, Grünebach F, Schmidt SM,
Müller MR, Boy D, Patrone F, Ballestrero A and Brossart P: The use
of dendritic cells in cancer immunotherapy. Crit Rev Oncol Hematol.
65:191–199. 2008. View Article : Google Scholar
|
|
19
|
Kuchroo VK, Das MP, Brown JA, Ranger AM,
Zamvil SS, Sobel RA, Weiner HL, Nabavi N and Glimcher LH: B7-1 and
B7-2 costimulatory molecules activate differentially the Th1/Th2
developmental pathways: Application to autoimmune disease therapy.
Cell. 80:707–718. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ranger AM, Das MP, Kuchroo VK, Glimcher LH
and Ploegh H: B7-2 (CD86) is essential for the development of
IL-4-producing T cells. Int Immunol. 8:1549–1560. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wojas-Turek J, Pajtasz-Piasecka E,
Rossowska J, Piasecki E and Duś D: Antitumor effect of murine
dendritic and tumor cells transduced with IL-2 gene. Folia
Histochem Cytobiol. 50:414–419. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cannon MJ, Goyne H, Stone PJB and
Chiriva-Internati M: Dendritic cell vaccination against ovarian
cancer - tipping the Treg/TH17 balance to therapeutic advantage?
Expert Opin Biol Ther. 11:441–445. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Galon J, Costes A, Sanchez-Cabo F,
Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M,
Berger A, Wind P, et al: Type, density, and location of immune
cells within human colorectal tumors predict clinical outcome.
Science. 313:1960–1964. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pajtasz-Piasecka E, Rossowska J, Szyda A,
Krawczenko A and Dus D: Generation of anti-tumor response by JAWS
II mouse dendritic cells transduced with murine interleukin 12
genes. Oncol Rep. 17:1249–1257. 2007.PubMed/NCBI
|
|
25
|
Lança T and Silva-Santos B: The split
nature of tumor-infiltrating leukocytes: Implications for cancer
surveillance and immunotherapy. Oncoimmunology. 1:717–725. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rossowska J, Anger N, Kicielińska J,
Pajtasz-Piasecka E, Bielawska-Pohl A, Wojas-Turek J and Duś D:
Temporary elimination of IL-10 enhanced the effectiveness of
cyclophosphamide and BMDC-based therapy by decrease of the
suppressor activity of MDSCs and activation of antitumour immune
response. Immunobiology. 220:389–398. 2015. View Article : Google Scholar
|
|
27
|
Escobar A, López M, Serrano A, Ramirez M,
Pérez C, Aguirre A, González R, Alfaro J, Larrondo M, Fodor M, et
al: Dendritic cell immunizations alone or combined with low doses
of interleukin-2 induce specific immune responses in melanoma
patients. Clin Exp Immunol. 142:555–568. 2005.PubMed/NCBI
|
|
28
|
Matias BF, de Oliveira TM, Rodrigues CM,
Abdalla DR, Montes L, Murta EFC and Michelin MA: Influence of
immunotherapy with autologous dendritic cells on innate and
adaptive immune response in cancer. Clin Med Insights Oncol.
7:165–172. 2013.PubMed/NCBI
|
|
29
|
Yamamoto M, Kamigaki T, Yamashita K, Hori
Y, Hasegawa H, Kuroda D, Moriyama H, Nagata M, Ku Y and Kuroda Y:
Enhancement of anti-tumor immunity by high levels of Th1 and Th17
with a combination of dendritic cell fusion hybrids and regulatory
T cell depletion in pancreatic cancer. Oncol Rep. 22:337–343.
2009.PubMed/NCBI
|
|
30
|
Guo C, Manjili MH, Subjeck JR, Sarkar D,
Fisher PB and Wang XY: Therapeutic cancer vaccines: Past, present,
and future. Adv Cancer Res. 119:421–475. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhu J and Paul WE: Heterogeneity and
plasticity of T helper cells. Cell Res. 20:4–12. 2010. View Article : Google Scholar
|
|
32
|
Baek S, Kim CS, Kim SB, Kim YM, Kwon SW,
Kim Y, Kim H and Lee H: Combination therapy of renal cell carcinoma
or breast cancer patients with dendritic cell vaccine and IL-2:
Results from a phase I/II trial. J Transl Med. 9:1782011.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Saha A and Chatterjee SK: Combination of
CTL-associated antigen-4 blockade and depletion of CD25 regulatory
T cells enhance tumour immunity of dendritic cell-based vaccine in
a mouse model of colon cancer. Scand J Immunol. 71:70–82. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cope A, Le Friec G, Cardone J and Kemper
C: The Th1 life cycle: Molecular control of IFN-γ to IL-10
switching. Trends Immunol. 32:278–286. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kicielińska J and Pajtasz-Piasecka E: The
role of IL-10 in the modulation of the immune response in normal
conditions and the tumor environment. Postepy Hig Med Dosw Online.
68:879–892. 2014.(In Polish). View Article : Google Scholar
|
|
36
|
Shoemaker J, Saraiva M and O'Garra A:
GATA-3 directly remodels the IL-10 locus independently of IL-4 in
CD4+ T cells. J Immunol. 176:3470–3479. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Koller FL, Hwang DG, Dozier EA and
Fingleton B: Epithelial interleukin-4 receptor expression promotes
colon tumor growth. Carcinogenesis. 31:1010–1017. 2010. View Article : Google Scholar : PubMed/NCBI
|
